Avalo Therapeutics, a clinical-stage biotech focused on IL-1β treatments, announced a public offering of common stock and pre-funded warrants. The company plans to use the proceeds to advance its lead drug abdakibart through Phase 3 trials and for general corporate purposes. Underwriters have a 30-day option to buy additional shares. The offering is subject to market conditions and regulatory approval, with detailed terms to be filed with the SEC soon.
Diana Burgon of Berkshire Hathaway HomeServices Bayside Realty was named to the 2025 Honor Society, recognizing the top 17% of sales professionals in the network. This award highlights her outstanding sales performance and dedication to clients. Sinc...
A new study found that adults with alcohol use disorder (AUD) who started treatment with GLP-1 receptor agonists like semaglutide and tirzepatide had significantly fewer alcohol-related hospitalizations compared to those on other diabetes or obesity ...
D.R. Horton reported Q3 earnings per share of $3.20, beating estimates, and revenues of $9.23 billion, slightly above expectations. Goldman Sachs raised its price target to $190 and maintained a "Buy" rating, signaling strong growth potential. Despit...
Interactive Brokers reported a strong Q2 with diluted EPS of $0.69 and net revenues of $1.90 billion, both exceeding analyst expectations. The company saw a 34% increase in client accounts and a 40% rise in client equity, driven by higher trading act...
Ondo surged 11.05% to $0.3997, leading altcoin gains driven by interest in its structured financial products in DeFi. Other notable rises include Rain (+9.31%), Venice Token (+7.92%), Aave (+6.90%), and Gram (+6.80%), each benefiting from sector-spec...
